Differential diagnosis of hepatitis E virus, cytomegalovirus and Epstein-Barr virus infection in patients with suspected hepatitis E

Fogeda, Marta; Ory, Fernando de; Avellón, Ana; Echevarría, José Manuel

doi:10.1016/j.jcv.2009.05.022

Cited by 68 publications

(63 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The lowest number of confirmed results by RIBT was obtained, in addition, among individuals younger than 20 years (31.6%). Primary infections by EpsteinBarr virus and cytomegalovirus are frequent in this population group, and both conditions have been shown to interfere anti-HEV testing [Fogeda et al, 2009].…”

Section: Discussionmentioning

confidence: 97%

Prevalence of specific antibody to hepatitis E virus in the general population of the community of Madrid, Spain

Fogeda

Avellón

Echevarría

2011

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

Hepatitis E virus (HEV) is an infectious agent causing hepatitis among humans. Although hepatitis E has been reported from many European countries, its incidence in Europe is largely unknown, and the prevalence of the HEV infection is also unknown for most countries of the region. Antibody to HEV (anti-HEV) was tested on 2,305 serum samples from the general population of the Community of Madrid (Spain) collected in the year 2008 among people aged 2-60 years. Total anti-HEV was tested by enzyme-immunoassay (EIA), and reactive samples were retested separately for anti-HEV IgG and IgM by recombinant immunoblot test (RIBT). Fifty samples (2.17%) displayed reactivity for total anti-HEV after EIA testing, and anti-HEV IgG was confirmed by RIBT in 25 (1.08%). The frequency of RIBT-confirmed anti-HEV ranged from 0.97% among the youngest to 3.61% among the oldest, and displayed a statistically significant trend to increasing with age. The rate of RIBT confirmation was also significantly higher among the individuals aged above 20 years old than among those younger of 21 years. HEV infection would be less frequent in the Community of Madrid than in Catalonia or the United Kingdom, and contact with HEV would be very uncommon among children and adolescents of the region. Confirmation of EIA-reactive samples by RIBT reduced the final numbers of anti-HEV testing as much as 50%, and some findings of this study suggest that such testing protocol would reflect better the real prevalence of anti-HEV in settings of low endemicity than the single testing by EIA.

show abstract

Section: Discussionmentioning

confidence: 97%

Prevalence of specific antibody to hepatitis E virus in the general population of the community of Madrid, Spain

Fogeda

Avellón

Echevarría

2011

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Studies with early anti-HEV IgM and IgG commercial assays often failed to detect seropositive individuals, undercounting the seroprevalence (200). Case reports and clinical studies from Europe have also raised suspicions about serologic cross-reactivity in the presence of other viral infections, such as Epstein-Barr virus (EBV) or cytomegalovirus (CMV) (201,202). Several recent serologic assays and other diagnostic methods have been found to have improved performance in a wide range of settings (194,198,(203)(204)(205)(206)(207).…”

Section: Scope and Duration Of Protective Immunity To Hev Following Imentioning

confidence: 99%

Host Immune Status and Response to Hepatitis E Virus Infection

2014

View full text Add to dashboard Cite

SUMMARY Hepatitis E virus (HEV), identified over 30 years ago, remains a serious threat to life, health, and productivity in developing countries where access to clean water is limited. Recognition that HEV also circulates as a zoonotic and food-borne pathogen in developed countries is more recent. Even without treatment, most cases of HEV-related acute viral hepatitis (with or without jaundice) resolve within 1 to 2 months. However, HEV sometimes leads to acute liver failure, chronic infection, or extrahepatic symptoms. The mechanisms of pathogenesis appear to be substantially immune mediated. This review covers the epidemiology of HEV infection worldwide, the humoral and cellular immune responses to HEV, and the persistence and protection of antibodies produced in response to both natural infection and vaccines. We focus on the contributions of altered immune states (associated with pregnancy, human immunodeficiency virus [HIV], and immunosuppressive agents used in cancer and transplant medicine) to the elevated risks of chronic infection (in immunosuppressed/immunocompromised patients) and acute liver failure and mortality (among pregnant women). We conclude by discussing outstanding questions about the immune response to HEV and interactions with hormones and comorbid conditions. These questions take on heightened importance now that a vaccine is available.

show abstract

“…Polyclonal IgM stimulation is well known in several viral infections, like Epstein-Barr virus (EBV), human cytomegalovirus (CMV), and parvovirus B19 infection (1,3,6,7,9), but it had not been described yet in PUUV infection. Thus, we investigated whether detection of IgM antibodies to pathogens which are not related to PUUV occurs more frequently in acute PUUV infection.…”

mentioning

confidence: 99%

Occurrence of Immunoglobulin M Antibodies against Several Bacterial and Viral Pathogens in Acute Hantavirus Infection

Wellinghausen

Goetz

Weber

2012

Clin Vaccine Immunol

View full text Add to dashboard Cite

Differential diagnosis of hepatitis E virus, cytomegalovirus and Epstein-Barr virus infection in patients with suspected hepatitis E

Cited by 68 publications

References 11 publications

Prevalence of specific antibody to hepatitis E virus in the general population of the community of Madrid, Spain

Prevalence of specific antibody to hepatitis E virus in the general population of the community of Madrid, Spain

Host Immune Status and Response to Hepatitis E Virus Infection

Occurrence of Immunoglobulin M Antibodies against Several Bacterial and Viral Pathogens in Acute Hantavirus Infection

Contact Info

Product

Resources

About